Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Trastutsumab Deruxtecan (DS-8201a) verrattuna tutkijan valintaan HER2-matala-rintasyöpään, joka on levinnyt tai jota ei voida poistaa kirurgisesti [DESTINY-Breast04]

tiistai 1. syyskuuta 2026 päivittänyt: Daiichi Sankyo

Vaihe 3, monikeskus, satunnaistettu, avoin, aktiivisesti kontrolloitu tutkimus DS-8201a:sta, anti-HER2-vasta-aine-lääkekonjugaatista (ADC) verrattuna lääkärin valitsemaan hoitoon rintasyöpäpotilaille, joilla on alhainen HER2-syöpä, ei leikattavissa ja/tai metastaattinen rintasyöpä

This study will compare DS-8201a to physician choice standard treatment.

Participants must have HER2-low breast cancer that has been treated before.

Participants' cancer:

  • Cannot be removed by an operation
  • Has spread to other parts of the body

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

This is a randomized, 2-arm, Phase 3, open-label, multicenter study to compare the safety and efficacy of trastuzumab deruxtecan versus the physician's choice (2:1) in HER2-low, unresectable and/or metastatic breast cancer participants.

The Sponsor proposes to define a new HER2-low population in this trial including tumors with IHC 1+ and IHC 2+/ISH- HER2 expression.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

557

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Brussels, Belgia, 1000
        • Institut Jules Bordet
      • Brussels, Belgia, 1090
        • Universitair Ziekenhuis Brussel
      • Brussels, Belgia, 1200
        • Cliniques Universitaires Saint-Luc
      • Leuven, Belgia, 3000
        • UZ Leuven
      • Loverval, Belgia, 6280
        • Grand Hôpital de Charleroi
      • Namur, Belgia, 5000
        • CHU UCL Namur
      • Tournai, Belgia, 7500
        • Centre Hospitalier Wallonie picarde - Site IMC
      • Barcelona, Espanja, 08036
        • Hospital Clinic de Barcelona
      • Barcelona, Espanja, 08035
        • Hospital Universitari Vall d'Hebron
      • Barcelona, Espanja, 08023
        • Hospital Quironsalud Barcelona
      • Barcelona, Espanja, 08003
        • Hospital del Mar
      • Madrid, Espanja, 28034
        • Hospital Universitario Ramon y Cajal
      • Madrid, Espanja, 28040
        • Hospital Universitario Clinico San Carlos
      • Madrid, Espanja, 28034
        • Hospital Ruber Internacional
      • Madrid, Espanja, 28033
        • MD Anderson Cancer Centre
      • Málaga, Espanja, 29010
        • Hospital Clinico Universitario Virgen de la Victoria
      • Seville, Espanja, 41009
        • Hospital Universitario Virgen Macarena
      • Seville, Espanja, 41013
        • Hospital Universitario Virgen del Rocio
      • Valencia, Espanja, 46014
        • Hospital General Universitario de Valencia
      • Valencia, Espanja, 46009
        • Instituto Valenciano de Oncologia IVO
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Espanja, 08908
        • ICO l'Hospitalet - Hospital Duran i Reynals
    • Guipuzcoa
      • San Sebastián, Guipuzcoa, Espanja, 20014
        • Hospital Universitario Donostia
    • La Coruña
      • A Coruña, La Coruña, Espanja, 15006
        • Complejo Hospitalario Universitario A Coruña
    • Tenerife
      • San Cristóbal de La Laguna, Tenerife, Espanja, 38320
        • Hospital Universitario de Canarias
    • Vizcaya
      • Bilbao, Vizcaya, Espanja, 48013
        • Hospital de Basurto
      • Daegu, Etelä -Korea, 41404
        • Kyungpook National University Chilgok Hospital
      • Seoul, Etelä -Korea, 03080
        • Seoul National University Hospital
      • Seoul, Etelä -Korea, 05505
        • Asan Medical Center
      • Seoul, Etelä -Korea, 06351
        • Samsung Medical Center
      • Seoul, Etelä -Korea, 06591
        • The Catholic University of Korea, Seoul St. Mary's Hospital
      • Seoul, Etelä -Korea, 120-752
        • Severance Hospital, Yonsei University Health System
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Etelä -Korea, 10408
        • National Cancer Center
      • Incheon, Gyeonggi-do, Etelä -Korea, 22332
        • Inha University Hospital
      • Seongnam-si, Gyeonggi-do, Etelä -Korea, 13620
        • Seoul National University Bundang Hospital
      • Suwon, Gyeonggi-do, Etelä -Korea, 16499
        • Ajou University Hospital
    • North Chungcheong
      • Cheongju-si, North Chungcheong, Etelä -Korea, 361-711
        • Chungbuk National University Hospital
      • Haifa, Israel, 3109601
        • Rambam Health Care Center
      • Jerusalem, Israel, 9103102
        • Shaare Zedek Medical Center
      • Jerusalem, Israel, 9112001
        • Hadassah University Hospital - Ein Kerem
      • Petah Tikva, Israel, 49100
        • Rabin Medical Center-Beilinson Campus
      • Ramat Gan, Israel, 52363
        • Chaim Sheba Medical Center
      • Rehovot, Israel, 7610001
        • Kaplan Medical Center
      • Safed, Israel, 13100
        • Ziv Medical Center
      • Tel Aviv, Israel, 6423906
        • Tel Aviv Sourasky Medical Center
      • Bologna, Italia, 40138
        • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
      • Brescia, Italia, 25100
        • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)
      • Catania, Italia, 95125
        • Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico
      • Catanzaro, Italia, 88100
        • Azienda Ospedaliero Universitaria Mater Domini-Campus Universitario
      • Milan, Italia, 20141
        • IEO Istituto Europeo di Oncologia
      • Naples, Italia, 80131
        • Istituto Nazionale Tumori Fondazione G. Pascale
      • Rimini, Italia, 47923
        • Ospedale degli Infermi
      • Roma, Italia, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      • Roma, Italia, 00133
        • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
    • Lecce
      • Tricase, Lecce, Italia, 73039
        • Azienda Ospedaliera Card. G. Panico
    • Milano
      • Monza, Milano, Italia, 20900
        • Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
      • Rozzano, Milano, Italia, 20089
        • Istituto Clinico Humanitas
    • Verona
      • Negrar, Verona, Italia, 37024
        • Ospedale Sacro Cuore Don Calabria
      • Innsbruck, Itävalta, 6020
        • Medizinische Universität Innsbruck
      • Linz, Itävalta, 4020
        • Kepler Universitätsklinikum
      • Salzburg, Itävalta, 5020
        • LKH - Universitätsklinikum der PMU Salzburg
      • Vienna, Itävalta, 1090
        • AKH - Medizinische Universität Wien (4305)
      • Wels, Itävalta, 4600
        • Klinikum Wels-Grieskirchen GmbH
    • Aichi-ken
      • Nagoya, Aichi-ken, Japani, 464-8681
        • Aichi Cancer Center Hospital
    • Chiba
      • Kashiwa-shi, Chiba, Japani, 277-8577
        • National Cancer Center Hospital East
    • Ehime
      • Matsuyama, Ehime, Japani, 791-0280
        • NHO Shikoku Cancer Center
    • Fukuoka
      • Fukuoka, Fukuoka, Japani, 811-1395
        • NHO Kyushu Cancer Center
    • Fukushima
      • Fukushima, Fukushima, Japani, 960-1295
        • Fukushima Medical University Hospital
    • Hiroshima
      • Hiroshima, Hiroshima, Japani, 730-8518
        • Hiroshima City Hiroshima Citizens Hospital
    • Hokkaido
      • Sapporo, Hokkaido, Japani, 003-0804
        • NHO Hokkaido Cancer Center
    • Hyōgo
      • Nishinomiya-shi, Hyōgo, Japani, 663-8501
        • Hyogo College of Medicine Hospital
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japani, 892-0833
        • Hakuaikai Sagara Hospital
    • Kanagawa
      • Isehara, Kanagawa, Japani, 259-1193
        • Tokai University Hospital
      • Yokohama, Kanagawa, Japani, 241-8515
        • Kanagawa Cancer Center
    • Osaka
      • Osaka, Osaka, Japani, 540-0006
        • NHO Osaka National Hospital
    • Osakasayama-shi
      • Onohigashi, Osakasayama-shi, Japani, 589-8511
        • Kindai University Hospital
    • Saitama
      • Kitaadachi-gun, Saitama, Japani, 362-0806
        • Saitama Cancer Center
    • Shizuoka
      • Sunto-gun, Shizuoka, Japani, 411-8777
        • Shizuoka Cancer Center
    • Tokyo-To
      • Kōtoku, Tokyo-To, Japani, 135-8550
        • Cancer Institute Hospital of JFCR
      • Minatoku, Tokyo-To, Japani, 105-8470
        • Toranomon Hospital
      • Shinagawa-Ku, Tokyo-To, Japani, 142-8666
        • Showa University Hospital
    • Alberta
      • Calgary, Alberta, Kanada, T2N4N2
        • Tom Baker Cancer Center
    • Ontario
      • Toronto, Ontario, Kanada, M4N 3M5
        • Toronto Sunnybrook Hospital
    • Quebec
      • Montreal, Quebec, Kanada, H2W 1S6
        • McGill University - Dept. Oncology Clinical Research Program
    • Anhui
      • Hefei, Anhui, Kiina, 230001
        • Anhui Provincial Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kiina, 100853
        • Chinese PLA General Hospital
      • Beijing, Beijing Municipality, Kiina, 100021
        • Cancer Hospital Chinese Academy of Medical Sciences
    • Fujian
      • Fuzhou, Fujian, Kiina, 350025
        • Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA
    • Guangdong
      • Guangzhou, Guangdong, Kiina, 510120
        • Sun Yat-sen Memorial hospital, Sun Yat-sen University
    • Heilongjiang
      • Harbin, Heilongjiang, Kiina, 150081
        • Harbin Medical University Cancer Hospital
    • Hubei
      • Wuhan, Hubei, Kiina, 430079
        • Hubei Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Kiina, 210008
        • The Affiliated Drum Tower Hospital of Nanjing University
    • Jilin
      • Changchun, Jilin, Kiina, 130000
        • The First Hospital of Jilin University
      • Changchun, Jilin, Kiina, 130012
        • Jilin Cancer Hospital
    • Liaoning
      • Shenyang, Liaoning, Kiina, 110042
        • Liaoning Cancer Hospital & Institute
    • Ningxia Hui
      • Yinchuan, Ningxia Hui, Kiina, 750004
        • General Hospital of Ningxia Medical University
    • Shandong
      • Linyi, Shandong, Kiina, 276001
        • Linyi Cancer Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kiina, 200080
        • Shanghai General Hospital
      • Shanghai, Shanghai Municipality, Kiina, 20032
        • Fudan University Shanghai Cancer Center
    • Sichuan
      • Chengdu, Sichuan, Kiina, 610041
        • West China Hospital, Sichuan University
    • Zhejiang
      • Hangzhou, Zhejiang, Kiina, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, Zhejiang, Kiina, 310016
        • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
      • Athens, Kreikka, 15125
        • Athens Medical Center
      • Athens, Kreikka, 11528
        • General Hospital of Athens "Alexandra"
      • Athens, Kreikka, 14564
        • General Oncology Hospital of Kifissia " Agioi Anargyroi"
      • Heraklion, Kreikka, 71110
        • University General Hospital of Heraklion
      • Larissa, Kreikka, 41110
        • University General Hospital of Larissa
      • Thessaloniki, Kreikka, 54622
        • Bioclinic Thessaloniki
      • Thessaloniki, Kreikka, 54645
        • Euromedica General Clinic Thessaloniki
      • Thessaloniki, Kreikka, 56429
        • General Hospital Papageorgiou
      • Thessaloniki, Kreikka, 57001
        • Interbalkan Hospital of Thessaloniki
      • Braga, Portugali, 4710-243
        • Hospital de Braga
      • Guimarães, Portugali, 4835-044
        • Centro Hospitalar do Alto do Ave, EPE
      • Lisbon, Portugali, 1649-035
        • Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria
      • Lisbon, Portugali, 1400-038
        • Fundação Champalimaud
      • Matosinhos Municipality, Portugali, 4464-509
        • Unidade Local de Saúde de Matosinhos, EPE (Hospital Pedro Hispano)
      • Porto, Portugali, 4200-072
        • Instituto Português de Oncologia do Porto Francisco Gentil, EPE
      • Porto, Portugali, 4099-001
        • Centro Hospitalar do Porto, E.P.E. - Hospital de Santo António
      • Santa Maria da Feira, Portugali, 4520-211
        • Centro Hospitalar de Entre o Douro e Vouga, E.P.E - Hospital de São Sebastião
      • Vila Nova de Gaia, Portugali, 4434-502
        • Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E
      • Vila Real, Portugali, 5000-508
        • Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE
      • Paris, Ranska, 75020
        • Hopital Tenon
      • Paris, Ranska, 75005
        • Institut Curie - site de Paris
    • Bouches-du-Rhône
      • Marseille, Bouches-du-Rhône, Ranska, 13009
        • Institut Paoli Calmettes
    • Calvados
      • Caen, Calvados, Ranska, 14076
        • Centre François Baclesse
    • Cotes d'Armor
      • Plérin, Cotes d'Armor, Ranska, 22190
        • CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
    • Finistere
      • Brest, Finistere, Ranska, 29609
        • CHU Brest - Hôpital Morvan
    • Gironde
      • Bordeaux, Gironde, Ranska, 33076
        • Institut Bergonié
    • Herault
      • Montpellier, Herault, Ranska, 34070
        • Clinique Clementville
      • Montpellier, Herault, Ranska, 34298
        • Institut Régional du Cancer de Montpellier
    • Ille Et Vilaine
      • Rennes, Ille Et Vilaine, Ranska, 35042
        • CRLCC Eugene Marquis
    • Loire Atlantique
      • Saint-Herblain, Loire Atlantique, Ranska, 44805
        • ICO - Site René Gauducheau
    • Loiret
      • Le Puy-en-Velay, Loiret, Ranska, 43012
        • Centre Hospitalier Emile Roux
    • Maine Et Loire
      • Angers, Maine Et Loire, Ranska, 49055
        • ICO - Site Paul Papin
    • Nord
      • Valenciennes, Nord, Ranska, 59322
        • Centre Hospitalier Valenciennes
    • Paris
      • Paris, Paris, Ranska, 75475
        • Hôpital Saint-Louis - Paris
    • Sarthe
      • Le Mans, Sarthe, Ranska, 72015
        • Clinique Victor Hugo - Centre Jean Bernard
    • Vaculuse
      • Avignon, Vaculuse, Ranska, 84918
        • Institut Sainte Catherine
    • Val De Marne
      • Saint-Mandé, Val De Marne, Ranska, 94160
        • Hôpital d'Instruction des Armees Begin*
      • Villejuif, Val De Marne, Ranska, 94805
        • Institut Gustave Roussy
      • Solna, Ruotsi, 17176
        • Karolinska universitetssjukhuset - Solna
      • Sundsvall, Ruotsi, 85186
        • Länssjukhuset Sundsvall-Härnösand
      • Uppsala, Ruotsi, 75185
        • Akademiska Sjukhuset
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Saksa, 69120
        • Universitaetsklinikum Heidelberg
    • Bavaria
      • Munich, Bavaria, Saksa, 81377
        • Klinikum der Universitaet Muenchen - Campus Grosshardern
      • Aarau, Sveitsi, 5000
        • Hirslanden Medical Center
      • Basel, Sveitsi, 4031
        • Universitaetsspital Basel
      • Chur, Sveitsi, 7000
        • Kantonsspital Graubuenden
      • Lausanne, Sveitsi, 1011
        • Centre Hospitalier Universitaire Vaudois
      • Sankt Gallen, Sveitsi, 9007
        • Kantonsspital St. Gallen
      • Winterthur, Sveitsi, 8401
        • Kantonsspital Winterthur
      • Zurich, Sveitsi, 8091
        • Universitaetsspital Zuerich
      • Kaohsiung City, Taiwan, 807
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Tainan, Taiwan, 704
        • National Cheng Kung University Hospital
      • Taipei, Taiwan, 100
        • National Taiwan University Hospital
      • Budapest, Unkari, 1097
        • Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
      • Budapest, Unkari, 1122
        • Orszagos Onkologiai Intezet
      • Debrecen, Unkari, 4032
        • Debreceni Egyetem
      • Gyula, Unkari, 5700
        • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
      • Nyíregyháza, Unkari, 4400
        • SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
      • Szolnok, Unkari, 5004
        • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
      • Moscow, Venäjä, 115478
        • FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
      • Moscow, Venäjä, 143423
        • SBIH of Moscow City "Moscow City Oncology Hospital №62" of Moscow Healthcare Departement
      • Yaroslavl, Venäjä, 150054
        • SBIH of Yaroslavl Region "Regional Clinical Oncological Hospital"
    • Cornwall
      • Truro, Cornwall, Yhdistynyt kuningaskunta, TR1 3LJ
        • Royal Cornwall Hospital
    • Greater London
      • London, Greater London, Yhdistynyt kuningaskunta, NW3 2QG
        • Royal Free Hospital
      • London, Greater London, Yhdistynyt kuningaskunta, EC1M 6BQ
        • Queen Mary University of London
      • London, Greater London, Yhdistynyt kuningaskunta, NW1 2PG
        • University College London Hospitals
    • Lothian Region
      • Edinburgh, Lothian Region, Yhdistynyt kuningaskunta, EH4 2XU
        • Western General Hospital
    • Nottinghamshire
      • Nottingham, Nottinghamshire, Yhdistynyt kuningaskunta, NG5 1PB
        • Nottingham University Hospitals City Campus
    • Surrey
      • Guildford, Surrey, Yhdistynyt kuningaskunta, GU2 7XX
        • Royal Surrey County Hospital
    • Arizona
      • Chandler, Arizona, Yhdysvallat, 85224
        • Ironwood Cancer & Research Centers - Chandler II
      • Gilbert, Arizona, Yhdysvallat, 85234
        • Banner MD Anderson Cancer Center
      • Goodyear, Arizona, Yhdysvallat, 85338
        • Cancer Treatment Centers of America at Western Regional Medical Center
    • California
      • Los Angeles, California, Yhdysvallat, 90095
        • UCLA School of Medicine
      • Palo Alto, California, Yhdysvallat, 94305
        • Stanford Cancer Institute
      • Redondo Beach, California, Yhdysvallat, 90277
        • Cancer Care Associates Medical Group, Inc. TORI
      • San Francisco, California, Yhdysvallat, 94158
        • University of California at San Francisco (PARENT)
    • Connecticut
      • Norwich, Connecticut, Yhdysvallat, 06360
        • Eastern Connecticut Hematology/Oncology Assoc.
    • Delaware
      • Newark, Delaware, Yhdysvallat, 19713
        • Christiana Care Health Services, Inc.
    • Florida
      • Boca Raton, Florida, Yhdysvallat, 33426
        • Sylvester Comprehensive Cancer Center - Deerfield Beach
      • Fort Myers, Florida, Yhdysvallat, 33916
        • Florida Cancer Specialists (South Region)
      • Hollywood, Florida, Yhdysvallat, 33021
        • Memorial Healthcare System MRH Cancer Center
      • Orlando, Florida, Yhdysvallat, 32806
        • Orlando Health, Inc.
      • Tampa, Florida, Yhdysvallat, 33139
        • Moffitt Cancer Center -Tampa
    • Georgia
      • Newnan, Georgia, Yhdysvallat, 30263
        • Cancer Treatment Centers of America-Georgia
    • Illinois
      • Chicago, Illinois, Yhdysvallat, 60637
        • University of Chicago Medical Center
      • Zion, Illinois, Yhdysvallat, 60099
        • Cancer Treatment Centers of America
    • Kansas
      • Wichita, Kansas, Yhdysvallat, 67214
        • Cancer Center of Kansas
    • Louisiana
      • New Orleans, Louisiana, Yhdysvallat, 70115
        • Touro Infirmary
    • Massachusetts
      • Boston, Massachusetts, Yhdysvallat, 02215
        • Dana-Farber Cancer Institute
    • Michigan
      • Detroit, Michigan, Yhdysvallat, 48202
        • Henry Ford Hospital
    • Missouri
      • Kansas City, Missouri, Yhdysvallat, 64111
        • Saint Luke's Hospital of Kansas City
    • New Jersey
      • Livingston, New Jersey, Yhdysvallat, 07039
        • Saint Barnabas Medical Center
    • New York
      • New York, New York, Yhdysvallat, 10016
        • New York University Medical Center
      • New York, New York, Yhdysvallat, 10065
        • Memorial Sloan Kettering Hospital
      • New York, New York, Yhdysvallat, 10065
        • Weill Cornell Medicine Breast Center
    • Ohio
      • Cleveland, Ohio, Yhdysvallat, 44195
        • The Cleveland Clinic Foundation
    • Oregon
      • Portland, Oregon, Yhdysvallat, 97239
        • Oregon Health & Science University
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Yhdysvallat, 15212
        • Allegheny General Hospital
      • Pittsburgh, Pennsylvania, Yhdysvallat, 15219
        • University of Pittsburgh Medical Center Health System
    • South Carolina
      • Greenville, South Carolina, Yhdysvallat, 29601
        • St Francis Hospital
    • Tennessee
      • Knoxville, Tennessee, Yhdysvallat, 37909
        • Brig Center for Cancer Care and Survivorship
      • Memphis, Tennessee, Yhdysvallat, 38120
        • Baptist Cancer Center
      • Nashville, Tennessee, Yhdysvallat, 37201
        • Tennessee Oncology - Skyline Satellite
    • Texas
      • Dallas, Texas, Yhdysvallat, 75234
        • BloomTrials Clinical Research, LLC
      • Houston, Texas, Yhdysvallat, 77030
        • The Methodist Hospital Research Institute
      • Houston, Texas, Yhdysvallat, 77030
        • University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics
    • Virginia
      • Fairfax, Virginia, Yhdysvallat, 22031
        • Virginia Cancer Specialists

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Is the age of majority in their country

  • Has pathologically documented breast cancer that:

    1. Is unresectable or metastatic
    2. Has low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)
    3. Is HR-positive or HR-negative
    4. Has progressed on, and would no longer benefit from, endocrine therapy
    5. Has been treated with 1 to 2 prior lines of chemotherapy/adjuvant in the recurrent or metastatic setting
    6. Was never previously HER2-positive (ICH 3+ or ISH+) on prior pathology testing (per American Society of Clinical Oncology-College of American Pathologists [ASCO-CAP] guidelines)
  • Has documented radiologic progression (during or after most recent treatment)

  • Has adequate archival tumor samples available or is wiling to provide fresh biopsies prior to randomization for:

    1. assessment of HER2 status
    2. assessment of post-treatment status
  • Has at least 1 measurable lesion per Response Evaluation Criteria In Solid Tumors 1.1

  • Has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood clotting functions

  • Male and female participants of reproductive/childbearing potential, agrees to follow instructions for method(s) of contraception and agrees to avoid preserving ova or sperm for at least 4.5 months after treatment (or longer, per locally approved labels)

Exclusion Criteria:

  • Is ineligible for all options in the physician's choice arm
  • Has breast cancer ever assessed with high-HER2 expression
  • Has previously been treated with any anti-HER2 therapy, including an antibody drug conjugate
  • Has uncontrolled or significant cardiovascular disease
  • Has spinal cord compression or clinically active central nervous system metastases
  • Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
  • Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Trastuzumab deruxtecan

HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a

DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously

Muut nimet:
  • DS-8201a
Active Comparator: Physician's Choice

HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:

  • Capecitabine
  • Eribulin
  • Gemcitabine
  • Paclitaxel
  • Nab-paclitaxel

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Aikaikkuna: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Eloonjäämistapahtumien kokonaismäärä (kuolemat)
Aikaikkuna: Satunnaistamisen päivämäärästä mistä tahansa syystä johtuvaan kuolemaan, enintään noin 3 vuotta
Satunnaistamisen päivämäärästä mistä tahansa syystä johtuvaan kuolemaan, enintään noin 3 vuotta
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status
Aikaikkuna: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Aikaikkuna: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients)
Aikaikkuna: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Aikaikkuna: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.

From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Overall Survival (OS) in All Patients
Aikaikkuna: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.

From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Best Overall Response and Confirmed Objective Response Rate (ORR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Aikaikkuna: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years

Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.

From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
Best Overall Response and Confirmed Objective Response Rate (ORR) in Participants With HER2-low Breast Cancer (All Patients)
Aikaikkuna: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years

Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.

From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
Duration of Response in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Aikaikkuna: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years

Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
Duration of Response in Participants With HER2-low Breast Cancer (All Patients)
Aikaikkuna: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years

Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
All-Cause Mortality
Aikaikkuna: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

All-cause mortality is defined as all anticipated and unanticipated deaths due to any cause, with the number and frequency of such events by arm or comparison group of the clinical study.

From the date of randomization up to the date of death due to any cause, up to approximately 3 years

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Opintojohtaja: Global Clinical Leader, Daiichi Sankyo

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Torstai 27. joulukuuta 2018

Ensisijainen valmistuminen (Todellinen)

Tiistai 11. tammikuuta 2022

Opintojen valmistuminen (Todellinen)

Tiistai 19. toukokuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 6. marraskuuta 2018

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 6. marraskuuta 2018

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 7. marraskuuta 2018

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 28. syyskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 1. syyskuuta 2026

Viimeksi vahvistettu

Tiistai 1. syyskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

IPD-jaon aikakehys

Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

IPD-jaon käyttöoikeuskriteerit

Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA
  • ICF

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa